Organon ‘Samsung’s Humira biosimilar to make KRW 100 billi

By Jung, Sae-Im | translator Kim, Jung-Ju

23.02.18 05:50:25

가나다라 0

Will release Hadlima in July...”Sales up to KRW 123.5 billion expected this year”

Approval as an interchangeable biosimilar expected by Q2 2024 in line with the approval of other competitors

Competition among biosimilars to start in earnest in 2024...” will rise as a leading product in the field”

Samsung Bioepeis’ U.S partner Organon projected that the sales of the company’s Humira biosimilar will reach a maximum of KRW 123.5 billion in the first year of its release.

On the 16th (local time), Organon projected so while presenting its full-year 2022 financial results, announcing that the company “will be launching the Humira biosimilar ‘Hadlima’ in the U.S. July this year.”

Hadlima is a Humira biosimilar that was developed by Samsung Bioepis. Humira is a blockbuster drug that held the ranks as the most-sold drug worldwide for a decade. Its global sales recorded USD 21.24 billion (approximately KRW 27 trillion) last year, of which sales in the U.S. accounted for USD 18.62 bil

Jung, Sae-Im (same@dailypharm.com)

If you want to see the full article, please JOIN US (click)